title: Pneumococcal Vaccine in Diabetes: Relevance in India.
abstract: Currently we have more than 65 million Diabetes patients in India with estimated 80 million prediabetics. Diabetes is a immunologically vulnerable population to develop all types of microbial infections. Pneumoccocal infections do have a substantial morbidity and mortality burden in the community. India has a large geriatric pool now which has substantially increased pneumococcal disease burden. Diabetes is a well-known risk factor for pneumococcal infection and predisposes individuals to nasopharyngeal colonization with the pneumococcus which is associated with invasive infection. In diabetics who are elderly, with chronic kidney or pulmonary disease and long standing duration of the disease with poor glycemic control are the highest risk group susceptible to invasive pneumococcal disease. With now availibilty of Pneumoccal vaccine in India, now it may be an preventive option which can be offered. Most global organisations recommend pneumococcal vaccination to diabetics.
authors.forename: R Joshi
authors.initials: RJ
authors.lastname: Shashank
authors.forename: S Joshi
authors.initials: SJ
authors.lastname: Samika
authors.forename: N Shah
authors.initials: NS
authors.lastname: Siddharth
mesh_terms: D003920:Diabetes Mellitus / Q000453:epidemiology / Q000276:immunology*; D006801:Humans; D016867:Immunocompromised Host / Q000276:immunology*; D007194:India / Q000453:epidemiology; D011008:Pneumococcal Infections / Q000517:prevention & control; D022242:Pneumococcal Vaccines / Q000627:therapeutic use*; D011018:Pneumonia, Pneumococcal / Q000276:immunology / Q000517:prevention & control*; D017410:Practice Guidelines as Topic
chemical_list: D022242:Pneumococcal Vaccines